On April 11, 2023, Shenzhen Neoimmune Co., Ltd launched its new product: NEO-SHM. This product is based on the independent multi-PCR library construction method developed by PanGen Medical and accurately calculates Ig-SHM (Somatic Hypermutation) through Next-Generation Sequencing (NGS). It provides evidence for the prognosis determination of CLL and the differential diagnosis of HCL/MCL/SMZL.
Background Introduction
To enhance the efficiency of antigen binding, the IGH gene in mature B cells undergoes mutations, primarily in the IGHV region, known as Somatic Hypermutation (SHM). The IGHV mutation rate represents the ratio of the sequence differences between the clonal cell gene and the homologous germline gene sequence. A rate greater than 2% indicates that the clone has undergone a significant SHM process.
1.Product Principle
The NEO-SHM analysis method launched by Shenzhen Neoimmune Co., Ltd is based on the independent multi-PCR library construction method developed by Shenzhen Neoimmune Co., Ltd. Using Next-Generation Sequencing (NGS) technology, it identifies clonal IgH rearrangements and tumor-specific rearrangement sequences. Additionally, it employs the Longest Common Substring algorithm to assemble and splice based on overlapping regions of the various products. This enables the assembly of a complete IGHV gene sequence from PE150 IgNGS data and the calculation of accurate SHM.


2.Clinical Significance

3.Data Support
The NGS detection of IGHV status in 49 CLL samples was completely consistent with Sanger sequencing results.

4.Comparison of Detection Technologies

